The association of hypnotics with incident cardiovascular disease and mortality in older women with sleep disturbances

Haines, Adam; Shadyab, Aladdin H.; Saquib, Nazmus; Kamensky, Victor; Stone, Katie L.; Wassertheil‐Smoller, Sylvia

doi:10.1016/j.sleep.2021.04.032

Cited by 11 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…hypnotics may be used for insomnia [ 42 ]. However, hypnotics have been associated with incident CVD and mortality in post-menopausal women [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

Insomnia as a predictor of recurrent cardiovascular events in patients with coronary heart disease

et al. 2022

View full text Add to dashboard Cite

Study Objectives Insomnia is highly prevalent in patients with coronary heart disease (CHD). However, the potential effect of insomnia on the risk of recurrent major adverse cardiovascular events (MACE) remains uncertain. Methods This prospective cohort study included 1082 consecutive patients 2–36 (mean 16) months after myocardial infarction and/or coronary revascularization. Data on clinical insomnia, coronary risk factors, and comorbidity were collected at baseline. Clinical insomnia was assessed using the Bergen Insomnia Scale (BIS). The primary composite endpoint of MACE (cardiovascular death, hospitalization due to myocardial infarction, revascularization, stroke, or heart failure) was assessed with an average follow-up of 4.2 (SD 0.3) years after baseline. Data were analyzed using Cox proportional hazard regression models stratified by prior coronary events before the index event. Results At baseline, mean age was 62 years, 21% were females, and 45% reported clinical insomnia. A total of 346 MACE occurred in 225 patients during the follow-up period. For clinical insomnia, the relative risk of recurrent MACE was 1.62 (95% confidence interval [CI]: 1.24–2.11, p < .001) adjusted for age, gender, and previous coronary events. In a multi-adjusted analysis, including coronary risk factors, cardiovascular comorbidity, symptoms of anxiety, and depression, the relative risk was 1.41 (95% CI: 1.05–1.89, p = .023). Clinical insomnia accounted for 16% of the MACE in attributable risk fraction analyses, being third in importance after smoking (27%) and low physical activity (21%). Conclusions Clinical insomnia was associated with increased risk of recurrent MACE. These results emphasize the importance of identifying and managing insomnia in CHD outpatients.

show abstract

“…hypnotics may be used for insomnia [ 42 ]. However, hypnotics have been associated with incident CVD and mortality in post-menopausal women [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

Insomnia as a predictor of recurrent cardiovascular events in patients with coronary heart disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Some studies have asserted a strong connection between specific drugs and cardiovascular disease. [10][11][12] We found that whether used in the long or short term, by heavy or casual users, there is a positive correlation between hypnotics and cardiovascular diseases, indicating its essential role in research. Therefore, we recommend that future research should include comprehensive details regarding the use of hypnotics, such as dosage and frequency, and incorporate them into propensity score matching or sensitivity analysis to obtain more rigorous research results.…”

mentioning

confidence: 75%

Correspondence to “association of sleep patterns and cardiovascular disease risk is modified by glucose tolerance status”

Chen,

Lin,

Sun

et al. 2024

Diabetes Metabolism Res

View full text Add to dashboard Cite

After reading the article written by Wang et al., we have encountered several concerns that may compromise the credibility of the article. There are some factors, such as changes in sleep patterns, glucose tolerance status, and the use of hypnotics, which may interfere with the research results. Additionally, the design of the sleep pattern could lead to biased outcomes. Therefore, we are writing this letter to recommend that further research should take these concerns into consideration.

show abstract

“…106 In addition, benzodiazepines and Z drugs have been found to be associated with an increased risk for falls and fractures among older adults as well as morbidity/mortality. [107][108][109]…”

Section: Pharmacologic Treatmentmentioning

confidence: 99%

Insomnia in primary care: Considerations for screening, assessment, and management

Yamamoto

Lim

Huang

et al. 2023

The Journal of Medicine Access

View full text Add to dashboard Cite

Insomnia, including insomnia disorder, is a common but often overlooked complaint in primary care settings. It is a risk factor for various medical and psychiatric diagnoses and is associated with substantial health care costs. While cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for insomnia disorder, access to CBT-I is limited. This article provides a pragmatic approach to screening, assessment, and treatment of insomnia in the primary care setting, promoting a population health approach. The authors review the role of CBT-I, treatment of comorbid conditions, and pharmacologic recommendations in working with primary care patients with insomnia. In addition, the authors highlight the potential utility of technology in improving access to insomnia care.

show abstract

The association of hypnotics with incident cardiovascular disease and mortality in older women with sleep disturbances

Cited by 11 publications

References 45 publications

Insomnia as a predictor of recurrent cardiovascular events in patients with coronary heart disease

Insomnia as a predictor of recurrent cardiovascular events in patients with coronary heart disease

Correspondence to “association of sleep patterns and cardiovascular disease risk is modified by glucose tolerance status”

Insomnia in primary care: Considerations for screening, assessment, and management

Contact Info

Product

Resources

About